A news item on MediGene AG in the Jan. 9, 2002, issue of BioWorld International should have said that in a survey following treatment of genital warts in a Phase III trial of Polyphenon E, the recurrence rate in men was 23 percent, not 25 percent, and clearance of warts occurred in 77 percent of men, not 25 percent.

Editor’s Note: The correction has been made in BioWorld Online.